|By Business Wire||
|May 15, 2014 09:14 AM EDT||
Effective immediately, anyone with a SAFE-BioPharma® identity credential will be able to sign a PDF document in Adobe® Acrobat® or Reader® that will be automatically trusted globally by any other user of Adobe Acrobat or Reader. This is the result of Adobe adding SAFE-BioPharma to its Adobe Approved Trust List (AATL).
SAFE-BioPharma is a global standard used throughout the life science and healthcare sectors to manage digital identities and to apply digital signatures to electronic documents. The standard requires, among other things, individuals to whom identity credentials are issued, to undergo a process creating a close bond between the credential and its user's proven identity. This process and other requirements provide high assurance of the individual's identity, allowing the credential to be used for a multitude of purposes, including applying legally binding, non-repudiable digital signatures to electronic documents.
The Adobe Approved Trust List (AATL) comprises almost 50 member organizations from around the world, including the U.S. government, Japanese government and members of the European Union Trust List.
"Inclusion on the Adobe Approved Trust List means that any person worldwide with a SAFE-BioPharma identity credential can sign a PDF document with full knowledge that the recipients will receive cost savings, while benefiting from the integrity-checking and trusted green checkmark/blue ribbon experience when opening the document," said Steve Gottwals, Senior Engineering Manager, Information Security, Adobe.
Both Acrobat and Reader are programmed to download a list of trusted digital certificates and will trust any digital signature created with a credential that traces a relationship to the high-assurance trustworthy certificates on the list.
Fully digital signatures as defined by the SAFE-BioPharma standard are required by the U.S. Drug Enforcement Agency for electronic prescriptions for controlled substances. They also are required by the European Medicines Agency for certain submissions and are used by EMA for outgoing correspondence requiring legally binding signatures.
"Forces within life science and healthcare demand technologies that deliver greater trust in cyber-transactions. The SAFE-BioPharma standard was created toward that end. Being a member of the Adobe Approved Trust List advances its utility for signing PDFs," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association, the non-profit industry collaborative that manages the standard.
Digital signatures based on the SAFE-BioPharma standard are used to sign electronic laboratory notebooks, regulatory submissions, clinical trial documents and routine day-to-day business documents. Digital identity credentials based on the SAFE-BioPharma standard are used to manage access across firewalls and to portals, and to access protected information, such as electronic health records.
For more information on the SAFE-BioPharma standard for digital identity and digital signatures used in life science and healthcare settings, visit http://www.safe-biopharma.org.
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.
May. 29, 2016 09:15 AM EDT Reads: 694
May. 29, 2016 08:15 AM EDT Reads: 2,725
May. 29, 2016 08:15 AM EDT Reads: 2,642
May. 29, 2016 07:00 AM EDT Reads: 2,285
May. 29, 2016 06:45 AM EDT Reads: 2,938
May. 29, 2016 06:30 AM EDT Reads: 627
May. 29, 2016 06:00 AM EDT Reads: 2,156
May. 29, 2016 06:00 AM EDT Reads: 1,338
May. 29, 2016 05:15 AM EDT Reads: 3,269
May. 29, 2016 05:00 AM EDT Reads: 1,968
May. 29, 2016 04:30 AM EDT Reads: 3,243
May. 29, 2016 03:30 AM EDT Reads: 977
May. 29, 2016 02:45 AM EDT Reads: 1,490
May. 29, 2016 02:30 AM EDT Reads: 1,349
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
May. 29, 2016 02:00 AM EDT Reads: 1,336